Scotiabank raised the firm’s price target on Regeneron (REGN) to $770 from $650 and keeps a Sector Perform rating on the shares. The firm is raising its price target on the stock due to “solid” execution as well as “positive vibes” following the recent upside surprise on Eylea HD approvals and ahead of 2026 data readouts, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN: